NYSE · Medical - Diagnostics & Research

CRL (CRL) Stock

$232.51 -0.90% NYSE: CRL Healthcare

Valuation

MetricValue
Price$232.51
Market Cap$11.20B
P/E Ratio-54.59
P/B Ratio2.42
P/S Ratio1.92
EPS (TTM)$0.00
52-Week High$237.14
52-Week Low$144.26
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-4.55%
ROA-2.02%
ROCE15.82%
Gross Margin12.63%
Operating Margin12.65%
Net Margin-4.59%
Debt/Equity1.04
Current Ratio1.29

Annual Financials (USD)

Metric20212022202320242025
Revenue$3.5B$4.0B$4.1B$4.0B$4.0B
Operating Profit$590.0M$651.0M$617.0M$227.0M$508.0M
Net Profit$391.0M$486.0M$475.0M$10.0M$-144.0M
EPS$7.60$9.48$9.22$0.20$-2.91
Op Margin16.7%16.4%14.9%5.6%12.7%

Balance Sheet (USD)

Metric20212022202320242025
Total Assets$7.0B$7.6B$8.2B$7.5B$7.1B
Total Liabilities$4.4B$4.6B$4.5B$4.0B$3.9B
Cash$245.0M$234.0M$277.0M$195.0M$214.0M
Borrowings$3.2B$3.1B$3.1B$2.7B$3.1B

Latest News

3 Healthcare Stocks We Approach with Caution StockStory · Jul 22, 2026 Charles River Laboratories Earnings Preview: What to Expect Barchart · Jul 20, 2026 What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now? Zacks · Jul 17, 2026 Charles River Laboratories International (CRL) Expands Cell Therapy Work, Is The Stock Still Undervalued? Simply Wall St. · Jul 17, 2026 Abbott Q2 Earnings & Revenues Top Estimates, Stock Up in Pre-market Zacks · Jul 16, 2026

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow$761.0M$620.0M$684.0M$735.0M$738.0M
Investing Cash Flow$-1.7B$-933.0M$-882.0M$-478.0M$-428.0M
Financing Cash Flow$3.0M$-62.0M$-10.0M$-139.0M$-416.0M
Net Cash Flow$13.0M$-5.0M$43.0M$-79.0M$10.0M
Free Cash Flow$532.0M$295.0M$365.0M$502.0M$518.0M

Valuation & Return Ratios

MetricValue
PEG Ratio—
EV / EBITDA11.53
FCF Yield5.07%
Quick Ratio1.03
Interest Coverage4.75
Return 1Y46.47%
Return 3Y6.31%
Return 5Y-44.21%

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
AVTR $13.36 -2.34% -9.79 $9.04B 0.00%
BAXBaxter International Inc. $23.18 +3.46% 11.25 $11.97B 0.88%
BIO $330.54 +4.47% 10.29 $8.94B 0.00%
CAI $16.45 +2.17% 49.96 $4.65B 0.00%
DVADaVita Inc. $236.58 +0.48% 23.20 $15.18B 0.00%

About CRL

CRL is led by CEO Birgit Girshick, employs 19,700 people, headquartered in Wilmington, US, publicly traded since 2000.

CRL stock trades at $232.51 with a market capitalization of $11.20B. The stock is valued at a price-to-earnings (P/E) ratio of -54.59, price-to-book of 2.42, price-to-sales of 1.92. Over the past 52 weeks the stock has ranged between $144.26 and $237.14, and currently trades 2.0% below its 52-week high.

On profitability, CRL generates a return on equity (ROE) of -4.55%, return on capital employed of 15.82%, an operating margin of 12.65%, a net profit margin of -4.59%.

Related Healthcare Stocks

LLY Drug Manufacturers - General $1185.71 -0.52% JNJ Drug Manufacturers - General $259.24 +0.88% ABBV Drug Manufacturers - General $246.04 +0.89% UNH Medical - Healthcare Plans $407.08 +0.77% MRK Drug Manufacturers - General $128.57 +0.16% NVS Drug Manufacturers - General $158.83 -0.64% NVO Biotechnology $51.58 +1.22% TMO Medical - Diagnostics & Research $594.00 +2.41% AMGN Drug Manufacturers - General $387.64 -1.39% ABT Medical - Devices $108.03 +0.70% GILD Drug Manufacturers - General $132.73 -1.18% PFE Drug Manufacturers - General $26.74 +2.06%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens featuring this stock

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksNYSE High ROE StocksAll stock screens
Run Stock Screener Investing Guides